THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE EU MARKET ABUSE REGULATION (596/2014). UPON THE PUBLICATION OF THE ANNOUNCEMENT […]
Wednesday October 24, 2018
UK government highlights global threat of AMR
Destiny Pharma plc (“Destiny Pharma” or the “Company”) Destiny Pharma’s lead asset, XF-73, well positioned to address the global threat of anti-microbial resistance highlighted in new UK government report Brighton, […]
Friday October 19, 2018
BIA celebrates UK bioscience innovative
Destiny Pharma plc (“Destiny Pharma” or the “Company”) BIA celebrates UK bioscience in creating innovative new drugs and treatment for patients A series of videos and explainer documents launched, focusing […]